Primary outcome measure: | |
To evaluate the efficacy of Gynoclear™ by change in endometriosis-related pain based on the Endometriosis pain daily diary v3 (EPDD) scores. | |
Secondary outcome measures: | |
To assess the change in health-related quality of life via the Endometriosis Health Profile (EHP-30), SF-12 and EQ. 5D scores. | |
To assess any changes in use of pharmaceutical analgesics via the EPDD | |
To assess any changes in dyspareunia (painful sexual intercourse) via the EPDD. | |
To assess any changes in fatigue via the EPDD and fatigue severity scale (FSS) | |
To assess any changes in restrictions to activities of daily living via the EPDD. | |
To monitor the frequency and severity of adverse events during intervention period. | |
To determine the cost-effectiveness of using Gynoclear™. | |
To explore participant satisfaction with the intervention. |